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Background: We investigated whether p42/p44 extracellular signal-regulated kinases (ERK1/2) and/or 
phosphatidylinositol-3-OH kinase (PI3K)-Akt play a crucial role in cardioprotection by κ-opioid receptor (KOP) 
activation.
Methods: Langendorff perfused rat hearts were subjected to 30 min of regional ischemia and 2 h of reperfusion. 
Antagonists of ERK1/2 and PI3K were perfused in hearts treated with the KOP agonist U50488H (U50). Infarct size 
was measured after 2 h of reperfusion. The phosphorylation states of ERK1/2 and Akt by Western immunoblots were 
determined. Drugs were perfused for a period of 5 min before and 30 min after reperfusion.
Results: Inhibition of ERK1/2 (26.8 ± 2.9%, P < 0.05 vs. U50) but not PI3K (15.5 ± 1.1%, P > 0.05 vs. U50) completely 
abrogated the anti-infarct effect of U50488H. Western blot analysis revealed a significant increase in ERK1/2 but not 
Akt phsophorylation in U50488H-treated hearts as compared to control hearts when measured immediately after 
reperfusion. 
Conclusions: KOP activation effectively reduces myocardial infarction. The anti-infarct effect of U50488H is mediated 
by the ERK1/2, but not the PI3K-Akt pathway. (Korean J Anesthesiol 2011; 60: 351-356)
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Introduction
    Opioids, which have been widely used clinically as anesthetic 
adjuvants or for pain control, can protect against myocardial 
ischemic-reperfusion (I/R) injury [1,2]. It has been well 
known that the activation of opioid receptors by ischemic 
preconditioning (I-Pre) or opioid-induced pharmacological 
pretreatment provides cardioprotection against myocardial I/R 
injury [3,4]. However, because pretreatment is seldom possible in 
acute myocardial infarction, ischemic postconditioning (I-Post) 
or reperfusion-targeted pharmacological strategies recently has 
generated considerable interest. Surprisingly, only a few studies 
thus far have investigated the effect of opioid receptor agonists 
administered solely during reperfusion in myocardial I/R injury. 
In addition, these studies were mainly focused on non-specific 
opioid receptor agonists or a δ-opioid receptor (DOP) agonist 
[2,5].
    The μ-, δ-, and κ-opioid receptors have been characterized 
pharmacologically. Binding and developmental studies have 
identified the presence of DOP and κ-opiod receptors (KOP) 
in the adult rat heart [6]. KOP are localized in both adult and 
neonatal rat hearts [7]. Although there is controversy regarding 
the role of KOP in myocardial I/R injury, a recent report 
demonstrated that activation of KOP by U50488H administered 
as a single bolus prior to reperfusion provided cardioprotection 
in intact rat hearts [8]. In an our recent report, we also showed 
that KOP activation early in the reperfusion period reduced 
myocardial infarction and improved cardiac function in isolated 
rat hearts [9]. However, the exact intracellular mechanism of 
cardioprotection by KOP activation is not well known. 
    Interestingly, the activation of reperfusion injury salvage 
kinase (RISK) signaling pathways, such as the p42/p44 
extracellular signal-regulated kinases (ERK1/2) and pro-
survival phosphatidylinositol-3-OH kinase (PI3K)-Akt cascades, 
at the time of reperfusion exerts cardioprotection against 
lethal myocardial reperfusion injury [9]. Cardioprotection 
by nonspecific opioid receptor agonists and a selective DOP 
agonist is known to occur via the PI3K-Akt signaling pathway [2], 
while the involvement of the ERK1/2 pathway is unclear. 
    The purpose of this study was to assess the role of the RISK 
signaling pathway, ERK1/2 and PI3K-Akt, in cardioprotection by 
exogenous KOP activation during reperfusion. 
Materials and Methods
    The experimental procedures and protocols used in this study 
were reviewed and approved by our institutional animal care 
and use committee.
Drugs and chemicals
    U50488H (a standard selective KOP agonist), LY294002 (a 
potent and selective PI3K inhibitor), and PD98059 (an ERK1/2 
specific inhibitor) were purchased from Tocris Bioscience 
(Ellisville, MO). 2,3,5-Triphenyltetrazolium chloride (TTC) 
was obtained from Sigma-Aldrich Chemical (St. Louis, MO). 
Fluorescent polymer microspheres were purchased from Duke 
Scientific (Palo Alto, CA). Antibodies against Akt and ERK1/2 
were purchased from Cell Signaling Technology Inc. (Beverly, 
MA). Other chemicals were obtained from Sigma-Aldrich 
Chemical.
Langendorff isolated heart perfusion preparation
    Male Sprague-Dawley rats (Korea Taconic Co, South Korea), 
weighing 280-330 gm were used for the experiments. They 
received 100 mg/kg of pentobarbital sodium and 300 IU of 
heparin intraperitoneally. Hearts were isolated and perfused 
with modified Krebs-Henseleit (KH) solution containing (in 
mM) 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.8 CaCl2, 24.8 NaHCO3, 
1.2 KH2PO4, and 10 glucose. Regional ischemia and reperfusion 
were induced as previously described [10]. In brief, a snare 
was made at the level of the proximal length of left coronary 
artery. Regional ischemia was induced by pulling the snare and 
confirmed by regional cyanosis and a substantial decrease in 
left ventricular developed pressure. Reperfusion was started by 
releasing the snare. 
Experimental protocol 
    All hearts were subjected to 30 min of regional ischemia and 
120 min of reperfusion, and each experimental group consisted 
of at least 7 hearts. In our previous report, the infarct volume 
as a percentage of ischemic volume in control hearts (CON) 
and 1 μM U50488H treated hearts (U50) were 27.2 ± 1.2% and 
12.2 ± 1.9%, respectively (P < 0.05) [9] and these results were 
compared to the following treatment groups to determine 
whether the RISK signaling pathway would play a critical role 
in KOP agonist-induced cardioprotection (n = 7 for all groups): 
1) U50 + LY; U50488H with 15 μM of LY294002, 2) U50 + PD; 
U50488H with 20 μM of PD98059, 3) LY; LY294002 alone, and 4) 
PD; PD98059 alone. 
    U50488H was dissolved in distilled water. LY294002 and 
PD98059 were dissolved in dimethyl sulfoxide. Drugs were 
perfused for a period of 5 min before and 30 min after 
reperfusion. The concentrations of all chemicals were based on 
our and other studies on isolated working rat hearts [9-11].353 www.ekja.org
Korean J Anesthesiol Kim, et al.
Exclusion criteria
    We decided prospectively that any hearts with a heart rate < 
250 beats/min, or coronary flow > 18 ml/min or < 8 ml/min 
at the end of stabilization would be excluded from the study. 
Hearts failing to develop left ventricular systolic pressure > 80 
mmHg when the left ventricular end diastolic pressure was 
kept at 5-10 mmHg were also excluded. Any heart exhibiting 
arrhythmia during the stabilization period also was discarded. 
Determination of area at risk and infarct size
    At the end of each experiment (after 2 h of reperfusion), the 
area at risk (AR) and area of necrosis (AN) were measured by 
TTC stain and quantified with Image Tool (UTHSCSA Image 
Tool, version 3.0) as described previously [12]. In brief, the 
coronary artery was re-occluded and fluorescent polymer 
microspheres were infused. The hearts were weighed, frozen, 
and cut into 2-mm slices. The slices were incubated in 1% TTC 
in sodium phosphate buffer 37
oC for 20 min. The slices were 
immersed in 10% formalin and then identified by illuminating 
the slices with UV light. The areas were converted into volumes 
by multiplying area by slice thickness. The AN volume was 
expressed as a percentage of the AR volume. All measurements 
were performed in a blinded fashion. There were no significant 
differences in body weight, heart weight, LV volume, AR 
volume, and AR/LV among the groups (Table 1). 
Tissue lysate preparation and Western immunoblot 
analysis
    Additional hearts were randomly assigned into a control 
group (n = 6) and a U50488H treatment group (n = 6), and were 
subjected to 30 min of regional ischemia followed by 5 min 
of reperfusion. Myocardial samples were taken from the AR 
region at 10 min before and 5 min after reperfusion. Samples 
were homogenized in ice-cold lysis buffer. Equal amounts of 
protein (50 μg/lane) were loaded, subjected to electrophoresis 
on SDS-polyacrylamide gel and transferred to a polyvinylidene 
difluoride membrane. Membranes were blocked with nonfat 
milk and then incubated with primary antibodies that recognize 
phosphorylation of Akt (protein kinase B) and ERK1/2 at 4
oC 
overnight. Bound primary antibodies were detected with a 
secondary anti-rabbit antibody and visualized by an enhanced 
chemiluminescence method. Data for total- and phospho-
ERK1/2 represent the sum of the 42- and 44-kDa bands.
Statistical analysis
    Data are presented as means ± SEM. Data analysis was 
performed with a personal computer statistical software 
package (SPSS for windows, Release 12.0; SPSS Inc, Chicago, 
IL). Data were analyzed using t-test and one-way analysis of 
variance (ANOVA) followed by a Bonferroni post-hoc testing. 
Differences were considered to be statistically significant when 
P values were less than 0.05. 
Table 1.  Morphometrics for Isolated Rat Hearts
Group Body weight (g) Heart weight (g) LV volume (cm
3) AR volume (cm
3) AR/LV (%)
CON
U50
U50 + LY
U50 + PD 
LY
PD
305.0 ± 5.8
301.9 ± 4.9
297.1 ± 4.2
302.1 ± 6.9
307.1 ± 2.4
308.6 ± 2.6
1.42 ± 0.02
1.40 ± 0.01
1.31 ± 0.03
1.42 ± 0.03
1.37 ± 0.05
1.39 ± 0.05
0.519 ± 0.020
0.534 ± 0.032
0.494 ± 0.022
0.517 ± 0.015
0.539 ± 0.013
0.552 ± 0.015
0.303 ± 0.014 
0.307 ± 0.021
0.302 ± 0.009
0.351 ± 0.012
0.302 ± 0.016
0.376 ± 0.023
58.7 ± 2.6
59.2 ± 5.7
61.5 ± 1.8
58.5 ± 3.0 
65.3 ± 2.2
68.0 ± 3.4
All values are mean ± SEM. CON: control, LV: left ventricle, AR: area at risk, U50: 1 μM of U50488H, LY: 15 μM of LY294002, PD: 20 μM of 
PD98059. 
Fig. 1. Area at necrosis (AN) as a percentage of area at risk (AR), 
evaluated by triphenyltetrazolium chloride staining following 30 
min of occlusion and 2 h reperfusion in an isolated rat heart model. 
Hearts were subjected to either control (CON), 1 μM U50488H (U50), 
15 μM LY294002 (LY), 20 μM PD98059 (PD), or U50 with LY or PD 
treatment. Each circle represents 1 heart. Horizontal bars depict 
mean of the group. AN: area of necrosis, AR: area at risk. Values are 
means ± SEM. *P < 0.05 vs. CON.354 www.ekja.org
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Results
Infarct size studies with ERK1/2 and PI3K and inhibitors
    As shown in Fig. 1, the ERK1/2 inhibitor PD98059 (26.8 ± 2.9%) 
completely blocked the anti-infarct effect of U50488H (P < 0.05 
vs. U50). However, there was no significant difference in AR/AN 
between the U50488H treatment group and the PI3K inhibitor 
LY294002 treatment group (15.5 ± 1.1%, P > 0.05 vs. U50). 
LY294002 or PD98059 itself did not alter infarct size (20.6 ± 2.2% 
for LY and 22.3 ± 1.7% for PD, P > 0.05 vs. CON). 
Western immunoblotting analysis of ERK1/2 and Akt
    To determine the involvement of the RISK pathway in the 
cardioprotective effect of KOP activation, we further measured 
ERK1/2 (Thr
202/Tyr
204) and protein kinase B or Akt (Ser
473) 
phosphorylation during reperfusion in perfused rat hearts. 
ERK1/2 phosphorylation significantly increased after 5 min 
of reperfusion compared to 10 min before reperfusion in both 
groups (189.3 ± 95.0% in CON and 534.1 ± 283.1% in U50, Fig. 2). 
Furthermore, U50488H-treated hearts had significant increases 
in ERK1/2 phosphorylation compared to control hearts (P < 
0.05) immediately after reperfusion. Myocardial sample taken 
from AR at 5 min of reperfusion revealed an increase in Akt 
phosphorylation compared with samples taken 10 min before 
reperfusion (303.1 ± 76.2% in CON and 242.9 ± 46.2% in U50). 
However, there was no significant difference between the two 
groups (P < 0.05, Fig. 3). 
Discussion
    In the present study, the anti-infarct effect by U50488H was 
totally abrogated by the ERK1/2 inhibitor PD98059. However, 
the PI3K inhibitor LY294002 could not block the infarct reducing 
effect of U50488H. And these results were corroborated by the 
phosphylation status of ERK1/2 and Akt kinases using Western 
immunoblott analysis. 
    The anti-infarct effect of U50488H in our previous study 
[9] was comparable with those previously reported for the 
nonspecific opioid receptor agonist morphine or the δ1-opioid 
receptor agonist BW373U86 [2]. And, these results are consistent 
with a recent report by the Gross group [8], who showed that 
administration of either DOP or KOP agonists as a single bolus 
Fig. 2. Western immunoblotting analysis of phospho- and total-
ERK1/2 (Thr
202/Tyr
204) in isolated rat hearts. Myocardial samples were 
obtained from the risk zone at 20 min of ischemia (I-20’) and 5 min 
(R-5’) after onset of reperfusion. Bar for R-5’ is phosphorylation of 
proteins at 5 min of reperfusion relative to the value of I-20’, expressed 
as means ± SEM of individual experimental observations. CON 
indicates control hearts. *P < 0.05 vs I-20’, 
†P < 0.05 vs. R-5’ (CON).
Fig. 3. Western immunoblotting analysis of phospho- and total-Akt 
(Ser
473) in isolated rat hearts. Myocardial samples were obtained 
from the risk zone at 20 min of ischemia (I-20’) and 5 min (R-5’) after 
onset of reperfusion. Bar for R-5’ is phosphorylation of proteins at 5 
min of reperfusion relative to the value of I-20’, expressed as means ± 
SEM of individual experimental observations. CON indicates control 
hearts. *P < 0.05 vs I-20’.355 www.ekja.org
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5 min prior to reperfusion provided infarct size-sparing effects 
in intact rat hearts. Collectively, these data strongly suggest that 
not only DOP but also KOP stimulation during the reperfusion 
phase plays a role in preventing lethal myocardial reperfusion 
injury. 
    The signaling mechanisms of opioid receptor activation are 
unveiling and seem to be similar to those of I-Pre and I-Post. 
In the present study, the infarct size-sparing effect of KOP 
activation by U50488H was totally blocked by the ERK1/2 
inhibitor PD98059 but not by the PI3K inhibitor LY294002, 
suggesting the involvement of ERK1/2 rather than PI3K-
Akt signaling pathway in cardioprotection by KOP activation 
during reperfusion. This finding was also corroborated by 
direct measurement of ERK1/2 and Akt kinases using Western 
blots. Meanwhile, Peart and colleagues [13] reported that pre-
treatment with the PI3K inhibitor wortmannin abolished 
infarct reduction by U50488H in in vivo rat hearts. Of note, 
however, we measured infarct size using ERK1/2 and PI3K 
antagonists in KOP activation in conjunction with assessing the 
phosphorylation status. Our present study highly implicates the 
involvement of ERK1/2 but not PI3K-Akt in the cardioprotection 
achieved with KOP activation during reperfusion. We do not 
know the exact reason for the discrepancy of results between 
our and Peart’s group, but the two pathways may also follow 
different spatio-temporal routes by KOP activation at early 
reperfusion, which should be defined in the future. 
    Meanwhile, the survival kinase cascades ERK1/2 and PI3K-
Akt may exhibit 'cross-talk' such that inhibiting of one cascade 
may activate the other and vice versa [14]. However, it does not 
seem that cross-talk always occurs. For instance, a recent study 
stressed the pivotal role of ERK1/2 but not PI3K/Akt in I-Post 
mediated cardioprotection [15]. In this regard, the relative 
importance of the two kinases in mediating the protection by 
KOP activation remains controversial. The results from our 
study suggest that ERK1/2 but not PI3K/Akt is the predominant 
mediator of KOP-induced protection. 
    Interestingly, some drugs protect the myocardium against 
ischemic but not against reperfusion injury and vice versa [16]. 
Accordingly, when administering drugs to prevent myocardial 
I/R injury, it is important to know whether it is protective only 
when given before ischemia and/or when given after ischemia 
during reperfusion. In this regard, it has been well accepted that 
DOP stimulation is effective not only during the pre-ischemic 
period but also during the reperfusion period [17]. Although 
it seems that KOP is less influential in I-Post [18], there have 
been data to suggest that exogenous activation of KOP have 
an infarct-sparing effect in the myocardial I/R model. Peart 
and colleagues [19] reported that exogenously induced KOP 
activation by three different KOP agonists (U50488, ICI204448, 
and BRL52537) 10 min before the onset of ischemia reduced 
infarct size in an intact rat model of myocardial infarction. 
However, thus far there is little in scientific examining the effect 
of infarct-sparing associated with KOP activation by sustained 
drug administration during the reperfusion phase. Combined 
with previous reports of cardioprotection by KOP treatment 
before index ischemia [12,19], our result strongly suggest that 
KOP activation confers cardioprotection not only when given 
before ischemia but also when given after ischemia during the 
reperfusion phase.
    In summary, our results suggest that sustained KOP activation 
targeting the reperfusion phase confers cardioprotection by 
the ERK1/2 subcellular signaling pathway but not the PI3K-Akt 
pathway. KOP activation during reperfusion, therefore, might 
be another cardioprotective mechanism. 
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